Last reviewed · How we verify

NCT06192485

Proactive and Reactive Balance Training Effects on Balance and Functional Performance Among Chronic Stroke Survivors

Completed NA Last updated 22 January 2025
What this trial tests

NA trial testing proactive balance training in Stroke in 40 participants. Completed in 28 May 2024.

Timeline
1 June 2023
Primary endpoint
31 January 2024
28 May 2024

Quick facts

Lead sponsorAl-Quds University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingsingle
Primary purposetreatment
Enrollment40
Start date1 June 2023
Primary completion31 January 2024
Estimated completion28 May 2024
Sites1 location across Palestinian Territories

Drugs / interventions tested

Conditions studied

Sponsor

Al-Quds University

Who can join

Adults 50 to 75, any sex, with Stroke or Chronic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is an RCT study, comparing the proactive and reactive balance training among stroke survivors, the participants will be chronic stroke patients aged between 50- 75 years old, and the participants will receive a balance training program for 8 weeks 3 sessions in the week, the participants will randomly be allocated in two groups proactive group and the reactive group, at the end of the study will compare the different effects between proactive and reactive balance training

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Al-Quds University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06192485.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing